Strong Results and Raised Guidance Pushed TransMedics Group (TMDX) in Q2 - InvestingChannel

Strong Results and Raised Guidance Pushed TransMedics Group (TMDX) in Q2

Janus Henderson Investors, an investment management company, released its “Janus Henderson Enterprise Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -2.84% in the second quarter, compared to the Russell Midcap Growth Index’s -3.21% return.  The firm is committed to a disciplined, risk-aware investment approach that considers fundamentals and relative valuations. In addition, please check the fund’s top five holdings to know its best picks in 2024.

Invesco Discovery Fund highlighted stocks like TransMedics Group, Inc. (NASDAQ:TMDX) in the Q2 2024 investor letter. TransMedics Group, Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company. The one-month return of TransMedics Group, Inc. (NASDAQ:TMDX) was -5.31%, and its shares gained 201.52% of their value over the last 52 weeks. On September 27, 2024, TransMedics Group, Inc. (NASDAQ:TMDX) stock closed at $159.14 per share with a market capitalization of $5.302 billion.

Invesco Discovery Fund stated the following regarding TransMedics Group, Inc. (NASDAQ:TMDX) in its Q2 2024 investor letter:

TransMedics Group, Inc. (NASDAQ:TMDX)offers transplant therapy for end-stage organ failure patients across multiple diseases. Management reported strong quarterly results and raised 2024 guidance above consensus expectations. The company has been helping to increase the size of the US transplant market as it has delivered more donor organs to recipients faster with its unique service offering.”

A surgeon in a modern operating theatre performing a transplant surgery with medical technology.

TransMedics Group, Inc. (NASDAQ:TMDX) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held TransMedics Group, Inc. (NASDAQ:TMDX) at the end of the second quarter which was 21 in the previous quarter. TransMedics Group, Inc.’s (NASDAQ:TMDX) total revenue in the second quarter of 2024 was $114.3 million, up 11.8% from Q1 2024 and 118% from Q2 2023. While we acknowledge the potential of TransMedics Group, Inc. (NASDAQ:TMDX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we discussed TransMedics Group, Inc. (NASDAQ:TMDX) and shared Carillon Eagle Small Cap Growth Fund’s views on the company. In addition, please check out our hedge fund investor letters Q2 2024 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire